File(s) under permanent embargo
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Version 2 2024-06-13, 15:00
Version 1 2021-11-29, 10:09
journal contribution
posted on 2024-06-13, 15:00 authored by MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, S Knop, C Doyen, P Lucio, Z Nagy, L Pour, M Cook, S Grosicki, A Crepaldi, AM Liberati, P Campbell, T Shelekhova, SS Yoon, G Iosava, T Fujisaki, M Garg, M Krevvata, Y Chen, J Wang, A Kudva, J Ukropec, S Wroblewski, M Qi, R Kobos, J San-MiguelOverall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
History
Journal
The LancetVolume
395Pagination
132-141Location
London, Eng.Publisher DOI
ISSN
0140-6736eISSN
1474-547XLanguage
engPublication classification
C1 Refereed article in a scholarly journalIssue
10218Publisher
The Lancet Publishing GroupUsage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC